What cohort studies can and cannot show about anabolic steroid use, mortality, cardiovascular outcomes, unnatural death, confounding and care thresholds.
On this page
Studies of anabolic steroid use and mortality look at death rates in selected groups, not a personal lifespan prediction. The main question is whether people identified as using anabolic androgenic steroids have higher rates of death, cardiovascular events, overdose, suicide, accidents or other outcomes than comparison groups. The answer needs cohort context, cause of death categories and careful limits.
Use emergency care now for chest pain, severe breathlessness, fainting, stroke signs, collapse, overdose concern, severe depression, psychosis, or immediate risk of self harm or harm to someone else.
What mortality research means
Mortality research counts deaths in a defined group over time. It may compare people with recorded AAS use to people without that record, or follow a clinic, registry or population sample. It can separate causes such as cardiovascular disease, cancer, accidents, suicide, overdose or unknown causes when those data are available.
This type of evidence can show an association. It cannot prove that every death was caused by steroids, and it cannot estimate how long one person will live. The result depends on who was counted, how AAS use was identified, which comparison group was used, and which other risks were measured.
What cohort studies can show
A cohort study follows a group across time. For AAS, cohort data can capture outcomes that smaller symptom studies miss, such as heart attacks, clots, arrhythmias, cardiomyopathy, heart failure, accidents, psychiatric events or death. Larger samples help, but they still depend on exposure records and confounder control.
A 2025 cardiovascular cohort study reported higher rates of several cardiovascular outcomes among people identified with AAS use. Those outcomes included cardiomyopathy and heart failure. It supports concern about long term harm, while still leaving questions about dose, duration, coexposures and individual risk.
Mortality papers may also identify unnatural death categories. That can include accidents, suicide, violence or overdose depending on the study design and registry coding. These outcomes may reflect a mix of steroid effects, other drug use, mental health, risk taking, environment and preexisting vulnerability.
Natural and unnatural causes of death
| Category | What it can include | Interpretation limit |
|---|---|---|
| Cardiovascular death | Heart attack, heart failure, arrhythmia, stroke or clot related outcomes. | Needs cause records and does not identify one mechanism by itself. |
| Unnatural death | Accidents, overdose, violence or suicide depending on coding. | Often mixed with social, psychiatric and other drug risks. |
| All cause death | Any recorded death in the follow up period. | Can hide which outcomes drove the signal. |
| No event recorded | No death or measured outcome during follow up. | Does not prove safety or future protection. |
Cardiovascular pathways
AAS exposure can sit beside high blood pressure, abnormal lipids, high hematocrit, kidney strain, sleep apnea, coronary plaque, arrhythmias and cardiomyopathy. These conditions can contribute to serious outcomes even when a person looks fit or trains heavily.
Cardiac imaging studies and reviews report differences in heart structure and function among AAS users. A 2026 review found lower left ventricular ejection fraction and worse strain measures in AAS users compared with nonusers in resistance trained samples. Imaging markers are not death outcomes, but they help explain why mortality and cardiovascular event studies matter.
See anabolic steroid cardiomyopathy, anabolic steroids and coronary artery disease, and anabolic steroids and cholesterol for condition specific owners.
Mental health and external causes
Some AAS users report mood swings, aggression, depression, anxiety, sleep problems, dependence, withdrawal symptoms or other substance use. After stopping, low mood and relapse pressure can become stronger for some people. These issues can influence injury, overdose, self harm and delayed care.
Mortality data cannot always separate steroid effects from alcohol, opioids, stimulants, psychiatric history, social stress or risk taking. That uncertainty should lead to broader safety planning, not dismissal. If severe mood symptoms or immediate danger appear, emergency help should override any plan to wait.
When symptoms need attention
Confounding and bias
Confounding means another factor may partly explain the outcome. AAS studies can be affected by training history, body size, smoking, alcohol, other drugs, socioeconomic factors, mental health, medical care access, genetics, preexisting disease and how exposure was recorded.
Selection bias can occur when only clinic patients, criminal justice records, anti doping cases or self selected survey participants are counted. Misclassification can occur when AAS use is hidden, denied, inaccurately recorded or based on one point in time. Stronger studies reduce these problems but do not remove every uncertainty.
What not to infer
- Do not turn a cohort result into a personal death date.
- Do not treat a normal workout, normal scan or normal lab as lifetime safety proof.
- Do not assume that stopping instantly removes all cardiovascular or mental health risk.
- Do not assume that a young age removes heart, clot, overdose or self harm risk.
- Do not use mortality research to justify a safer cycle, dose or stack.
Questions for care
Ask which immediate symptoms need emergency care, which cardiovascular tests fit your history, which mental health symptoms need support, how blood pressure, lipids and hematocrit will be followed, and which other substances or medicines change risk. Bring dates, products, injection or oral routes, coexposures and prior results.
Read how to talk with a doctor about anabolic steroid use for disclosure planning and help for anabolic steroid use for support routes.
Related reading
- Anabolic steroids and cardiovascular health
- Anabolic steroid warning signs
- Anabolic steroids and mental health
- Blood tests during anabolic steroid use
References
- Cardiovascular disease in anabolic androgenic steroid users. Circulation, 2025.
- Anabolic androgenic steroids on cardiac structure and function in resistance trained athletes. International Journal of Cardiology, 2026.
- Anabolic androgenic steroid use and mortality cohort evidence. 2024.
- Anabolic androgenic steroid health outcomes review. 2024.
- Adverse health consequences of performance enhancing drugs. Endocrine Reviews, 2014.